Regeneron Pharmaceuticals Inc (REGN)
737.85
-6.65
(-0.89%)
USD |
NASDAQ |
Nov 22, 16:00
739.01
+1.16
(+0.16%)
After-Hours: 17:25
Regeneron Pharmaceuticals Research and Development Expense (Quarterly): 1.272B for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 1.272B |
| June 30, 2024 | 1.20B |
| March 31, 2024 | 1.248B |
| December 31, 2023 | 1.177B |
| September 30, 2023 | 1.075B |
| June 30, 2023 | 1.085B |
| March 31, 2023 | 1.101B |
| December 31, 2022 | 1.043B |
| September 30, 2022 | 911.30M |
| June 30, 2022 | 794.30M |
| March 31, 2022 | 843.80M |
| December 31, 2021 | 737.60M |
| September 30, 2021 | 665.40M |
| June 30, 2021 | 714.20M |
| March 31, 2021 | 742.90M |
| December 31, 2020 | 744.50M |
| September 30, 2020 | 684.60M |
| June 30, 2020 | 722.00M |
| March 31, 2020 | 583.90M |
| December 31, 2019 | 552.40M |
| September 30, 2019 | 526.00M |
| June 30, 2019 | 885.50M |
| March 31, 2019 | 486.10M |
| December 31, 2018 | -116.00M |
| September 30, 2018 | 557.00M |
| Date | Value |
|---|---|
| June 30, 2018 | 529.30M |
| March 31, 2018 | 498.60M |
| December 31, 2017 | 527.94M |
| September 30, 2017 | 529.75M |
| June 30, 2017 | 509.98M |
| March 31, 2017 | 507.44M |
| December 31, 2016 | 479.21M |
| September 30, 2016 | 543.05M |
| June 30, 2016 | 559.93M |
| March 31, 2016 | 470.11M |
| December 31, 2015 | 461.21M |
| September 30, 2015 | 425.92M |
| June 30, 2015 | 390.33M |
| March 31, 2015 | 343.11M |
| December 31, 2014 | 351.74M |
| September 30, 2014 | 337.73M |
| June 30, 2014 | 294.50M |
| March 31, 2014 | 287.38M |
| December 31, 2013 | 268.14M |
| September 30, 2013 | 224.04M |
| June 30, 2013 | 187.46M |
| March 31, 2013 | 180.30M |
| December 31, 2012 | 181.02M |
| September 30, 2012 | 158.30M |
| June 30, 2012 | 147.37M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
552.40M
Minimum
Dec 2019
1.272B
Maximum
Sep 2024
894.94M
Average
819.05M
Median
Research and Development Expense (Quarterly) Benchmarks
| Amgen Inc | 1.45B |
| Eli Lilly and Co | 2.734B |
| Pfizer Inc | 2.598B |
| Biogen Inc | 542.70M |
| AbbVie Inc | 2.13B |